Ophthalmology Times - Ophthalmology news, articles, and events
WEBEyeCon 2024: Key takeaways for enhanced patient care from Day 1. This Week in Ophthalmology: Week of September 22, 2024. EyeCon 2024: Peter McDonnell, MD, and Laura Periman, MD, on the importance of integrating new knowledge into practice. Eyecon 2024: Thyroid Eye Disease in focus. Retina Society 2024: A …
Physicians sort out pros and cons of several new IOLs on the market
WEBNov 12, 2021 · The new IOL in the EDoF category is the AcrySof IQ Vivity (Alcon). The Vivity uses wavefront-shaping technology on its anterior surface that elongates the depth of focus, giving about a 1.5 D range of vision. Because it is a nondiffractive lens, risks of glare and halos are minimized and quality of vision is better than with a multifocal IOL.
IPL + thermal pulsation: A thorough approach to dry eye
WEBNov 6, 2018 · This one-two punch approach is logical: IPL treats inflammation, the underlying cause of dry eye disease. Thermal pulsation addresses meibomian gland dysfunction (MGD), a major component of dry eye pathology, by unclogging the glands and evacuating their abnormal content. When we treat both the inflammatory source and the resulting clogged ...
Study suggests potential link between semaglutide and risk of non ...
WEBJul 9, 2024 · Boston researchers led by first author Jimena Tatiana Hathaway, MD, MPH, reported that there is a potential risk of the development of non-arteritic ischemic optic neuropathy (NAION) 1 associated with prescriptions for semaglutide (Wegovy, Ozempic, Novo Nordisk). Prescriptions with semaglutide are FDA approved to treat obesity and type 2 diabetes, respectively.
The first steps in gene therapy for achromatopsia
WEBMay 14, 2021 · The first steps in gene therapy for achromatopsia. May 14, 2021. By Lynda Charters. Article. Mark Pennesi, MD, PhD, reports during ARVO 2021 that preliminary results have shown that AGTC-401 and AGTC-402 seem safe and well tolerated in patients with ACHM. Reviewed by Mark E. Pennesi, MD, …
Breaking down the dorzolamide shortage - Ophthalmology Times
WEBAug 9, 2019 · Essentially, brimonidine 0.1% (Alphagan P, Allergan) is often a reasonable substitution for dorzolamide, while brimonidine-timolol (Combigan, Allergan) is an ideal substitution for dorzolamide-timolol shortages, assuming no brimonidine allergy. Certainly, the dorzolamide shortage has helped us view branded pharmaceutical companies in …
Managing conjunctival pigmented lesions - Ophthalmology Times
WEBJun 15, 2017 · Conjunctival nevus tends to be pigmented and asymptomatic with a low risk for transformation into melanoma, somewhere under 1%, said Dr. Shields, co-director, Oncology Service, Wills Eye Hospital, and professor of ophthalmology at Thomas Jefferson University in Philadelphia. PAM tends to occur in Caucasians, is …
New treatment reduces corneal oedema after cataract surgery
WEBMay 1, 2015 · Nourouzi et al., Am J Ophthalmol. 2006;142 (4):671-673. Occasionally, post-cataract surgery endothelial cells don’t function well enough to keep the cornea clear, which can commonly cause corneal oedema. Here, Prof. Feinbaum describes a new treatment modality that has been designed to reduce and in most cases stop the …
Myths and misconceptions about autologous serum for dry eye
WEBJun 22, 2020 · Special to Ophthalmology Times® Autologous serum eye drops (ASEDs) have become a mainstay of therapy for certain categories of patients with dry eye and those with underlying immunologic disease or poor epithelial healing.. The logistics of prescribing ASEDs have changed dramatically in the past few years, making their use far more convenient for patients and physicians alike.
EDTA chelation provides solution for band keratopathy
WEBOct 15, 2005 · Baltimore—Ethylene diamine tetra-acetic acid (EDTA) chelation offers a low-tech, low-cost, effective treatment for calcific band keratopathy associated with chronic uveitis and other disorders, said James P. Dunn, MD, at the Current Concepts in Ophthalmology meeting, sponsored by Johns Hopkins University School of Medicine and Ophthalmology Times.